Kevin Thornal Sells 5,691 Shares of Zimmer Biomet (NYSE:ZBH) Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) insider Kevin Thornal sold 5,691 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Zimmer Biomet Stock Up 2.0%

Zimmer Biomet stock traded up $1.91 during midday trading on Tuesday, hitting $98.45. The stock had a trading volume of 3,615,966 shares, compared to its average volume of 2,264,630. The stock has a market cap of $18.78 billion, a P/E ratio of 23.95, a P/E/G ratio of 1.76 and a beta of 0.47. The business has a fifty day moving average price of $95.68 and a 200 day moving average price of $91.45. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $106.88.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter last year, the company posted $2.07 earnings per share. Zimmer Biomet’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Canaccord Genuity Group upped their target price on Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research note on Thursday, August 6th. Zacks Research raised Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 25th. Royal Bank Of Canada upped their price objective on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $96.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $104.42.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ZBH. BlackRock Inc. acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth $1,344,282,000. Franklin Resources Inc. lifted its holdings in shares of Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after purchasing an additional 2,017,857 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Zimmer Biomet by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock valued at $468,821,000 after purchasing an additional 36,611 shares during the period. Primecap Management Co. CA acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at $328,578,000. Finally, Van ECK Associates Corp increased its stake in Zimmer Biomet by 3.9% in the 4th quarter. Van ECK Associates Corp now owns 3,613,425 shares of the medical equipment provider’s stock worth $324,920,000 after purchasing an additional 136,519 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.